NEW YORK, May 3 – Deltagen’s first quarter revenues rose to $2.5 million, compared to $286,000 for the first quarter of 2000.

The company attributed this surge to subscription revenue from its DeltaBase mammalian gene function database. Pfizer and GlaxoSmithkline both subscribed to the database in the latter part of 2000, and Deltagen has additional ongoing agreements with Schering-Plough and Merck.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A research duo estimates in PLOS One the number of papers that have used misidentified cell lines.

UK's National Institute for Health and Care Excellence approves GlaxoSmithKline's SCID gene therapy despite cost.

Science reports that Brazilian researchers are petitioning for the reversal of budget cuts.

In PLOS this week: gene flow patterns in common ash, guidelines for using morpholinos in zebrafish, and more.